Target intelligence / Profile preview

T cell receptor alpha joining 21 (TRAJ21)

Target
TRAJ21
Molecular classification
T cell receptor joining gene segment, Immunoglobulin superfamily (as part of the T cell receptor gene loci)
01

Overview

T cell receptor alpha joining 21 (TRAJ21) is a gene segment located within the TCR alpha locus in humans and mice. It encodes a joining (J) region element used during the somatic VJ (variable-joining) recombination process in developing T cells, which permits immense diversity within the antigen-recognition sites of T cell receptors (TCRs). The TRAJ21 segment does not encode a functional protein on its own but is incorporated into the mature TCR alpha chain when recombined with a variable (Vα) gene segment and the constant (Cα) region in developing T cells. Its role is conserved across species and is essential for generation of TCR diversity, but it is not a direct therapeutic, drug, or diagnostic target[1][4][6]. In summary: TRAJ21 is a J-gene segment of the TCR alpha locus, essential for adaptive immunity, but is not a distinct receptor, nor a direct therapeutic target or biomarker. Any reference to it as a druggable target or receptor is incorrect, though it is functionally indispensable for T cell antigen recognition[1][4][6].

Other names
TRAJ21Traj21 (in mouse)T cell receptor alpha joining 21
02

Mechanism of action

Null. Not applicable, as there are no drugs that interact directly with this gene segment.

03

Biological functions

V(D)J recombination (joins with variable (V) segments to form the antigen-binding domain of the TCR alpha chain)Immune response (indirectly, as a component in TCR diversity generation)
04

Disease associations

Not a direct disease marker or target. However, aberrations in TCR recombination can contribute to immunodeficiencies or lymphoid malignancies, but these are general to the recombination machinery, not the TRAJ21 segment itself.

Beyond the preview

Go deeper on T cell receptor alpha joining 21 (TRAJ21).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T cell receptor alpha joining 21 (TRAJ21).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call